CY1125066T1 - Πολυκυκλικα αμιδικα παραγωγα ως αναστολεις cdk9 - Google Patents
Πολυκυκλικα αμιδικα παραγωγα ως αναστολεις cdk9Info
- Publication number
- CY1125066T1 CY1125066T1 CY20211101125T CY211101125T CY1125066T1 CY 1125066 T1 CY1125066 T1 CY 1125066T1 CY 20211101125 T CY20211101125 T CY 20211101125T CY 211101125 T CY211101125 T CY 211101125T CY 1125066 T1 CY1125066 T1 CY 1125066T1
- Authority
- CY
- Cyprus
- Prior art keywords
- cancer
- alkyl
- optionally substituted
- treatment
- membered heterocycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Polyesters Or Polycarbonates (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Detergent Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Παρέχονται μια σειρά από νέα παράγωγα πυριδίνης ή πυριμιδίνης του τύπου Ι που αναστέλλουν την CDK9 και μπορεί να είναι χρήσιμα για τη θεραπευτική αγωγή υπερπολλαπλασιαστικών ασθενειών. Ειδικότερα, οι ενώσεις χρησιμοποιούνται στη θεραπευτική αγωγή πολλαπλασιαστικών ασθενειών όπως ο καρκίνος, που περιλαμβάνουν αιματολογικές κακοήθειες όπως οξεία μυελογενή λευχαιμία, πολλαπλό μυέλωμα, χρόνια λεμφοκυτταρική λευχαιμία, διάχυτο λέμφωμα μεγάλων Β κυττάρων, λέμφωμα Burkitt, θυλακιώδες λέμφωμα και συμπαγείς όγκους όπως ο καρκίνος του μαστού, ο καρκίνος του πνεύμονα, το νευροβλάστωμα και ο καρκίνος του παχέος εντέρου. Το Α είναι C(R5) ή Ν· το R5 είναι Η, Cl - 3 αλκύλιο, CN ή αλογόνο· το R2 είναι προαιρετικώς υποκατεστημένο 3-7 μελές ετεροκυκλο αλκύλιο ή 3-7 μελές κυκλοαλκύλιο· το R4 είναι όπου τα Χ και Υ μαζί με τα άτομα στα οποία προσαρτώνται σχηματίζουν έναν προαιρετικώς υποκατεστημένο, κορεσμένο ή μερικώς κορεσμένο 5 έως 7 μελή ετεροκυκλοαλκυλο δακτύλιο ο οποίος, επιπλέον του αζώτου γέφυρας, μπορεί να περιέχει ένα ή δυο ετεροάτομα που επιλέγονται από Ν, Ο και S· το J είναι Ν ή CR11· και το R11 είναι Η ή C1 - 3 αλκύλιο.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562185852P | 2015-06-29 | 2015-06-29 | |
| PCT/EP2016/064899 WO2017001354A1 (en) | 2015-06-29 | 2016-06-27 | Polycyclic amide derivatives as cdk9 inhibitors |
| EP16733459.8A EP3313838B1 (en) | 2015-06-29 | 2016-06-27 | Polycyclic amide derivatives as cdk9 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1125066T1 true CY1125066T1 (el) | 2023-03-24 |
Family
ID=56292699
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191100636T CY1122111T1 (el) | 2015-06-29 | 2019-06-19 | Παραγωγα πολυκυκλικου αμιδιου ως cdk9 αναστολεις |
| CY20211101125T CY1125066T1 (el) | 2015-06-29 | 2021-12-22 | Πολυκυκλικα αμιδικα παραγωγα ως αναστολεις cdk9 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191100636T CY1122111T1 (el) | 2015-06-29 | 2019-06-19 | Παραγωγα πολυκυκλικου αμιδιου ως cdk9 αναστολεις |
Country Status (36)
| Country | Link |
|---|---|
| US (4) | US9845331B2 (el) |
| EP (2) | EP3313838B1 (el) |
| JP (1) | JP6997627B2 (el) |
| KR (1) | KR102663113B1 (el) |
| CN (1) | CN107873028B (el) |
| AR (1) | AR105179A1 (el) |
| AU (1) | AU2016286200B2 (el) |
| BR (1) | BR122019013677B1 (el) |
| CA (1) | CA2989499C (el) |
| CL (1) | CL2017003306A1 (el) |
| CO (1) | CO2017013713A2 (el) |
| CR (2) | CR20210297A (el) |
| CY (2) | CY1122111T1 (el) |
| DK (2) | DK3313838T3 (el) |
| DO (2) | DOP2017000295A (el) |
| EA (1) | EA035383B1 (el) |
| ES (2) | ES2728356T3 (el) |
| HR (2) | HRP20211970T1 (el) |
| HU (2) | HUE043440T2 (el) |
| IL (1) | IL256393B (el) |
| LT (2) | LT3313838T (el) |
| ME (1) | ME03404B (el) |
| MX (1) | MX371034B (el) |
| NI (1) | NI201700174A (el) |
| PE (1) | PE20180530A1 (el) |
| PH (1) | PH12017502334A1 (el) |
| PL (2) | PL3313838T3 (el) |
| PT (2) | PT3539961T (el) |
| RS (2) | RS58712B1 (el) |
| SI (2) | SI3313838T1 (el) |
| SV (1) | SV2017005598A (el) |
| TN (1) | TN2017000486A1 (el) |
| TR (1) | TR201909286T4 (el) |
| TW (1) | TWI723028B (el) |
| WO (1) | WO2017001354A1 (el) |
| ZA (1) | ZA201800563B (el) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020005039A2 (pt) | 2017-09-25 | 2020-09-15 | Astrazeneca Ab | combinação de um inibidor de btk e um inibidor de cdk9 para tratar câncer |
| US11319295B2 (en) | 2017-10-09 | 2022-05-03 | Merck Sharp & Dohme Corp. | Substituted phenyloxetane and phenyltetrahydrofuran compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors |
| CN108129288B (zh) * | 2017-12-27 | 2021-01-22 | 上海毕得医药科技股份有限公司 | 一种反式-3-羟基环丁基甲酸的合成方法 |
| TW202344250A (zh) | 2018-11-14 | 2023-11-16 | 瑞典商阿斯特捷利康公司 | 治療癌症之方法 |
| KR20220079851A (ko) * | 2019-09-11 | 2022-06-14 | 프렐루드 테라퓨틱스, 인코포레이티드 | Cdk 억제제 및 약제로서의 이의 용도 |
| US20230102081A1 (en) * | 2019-12-09 | 2023-03-30 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | Compound as cyclin-dependent kinase 9 inhibitor and use thereof |
| US20230219961A1 (en) * | 2020-05-12 | 2023-07-13 | Suzhou Alphama Biotechnology Co., Ltd. | Pyridine acetamide derivative serving as CDK inhibitor, and preparation method therefor and use thereof |
| WO2021227904A1 (zh) * | 2020-05-12 | 2021-11-18 | 苏州阿尔脉生物科技有限公司 | 一种作为cdk9抑制剂的多环酰胺类衍生物、其制备方法及用途 |
| JP2023542065A (ja) | 2020-06-24 | 2023-10-05 | アストラゼネカ ユーケー リミテッド | 抗体－薬物複合物及びｃｄｋ９阻害剤の組み合わせ |
| WO2022028556A1 (zh) | 2020-08-07 | 2022-02-10 | 南京药石科技股份有限公司 | Cdk9抑制剂及其用途 |
| TWI809330B (zh) * | 2020-11-20 | 2023-07-21 | 大陸商勁方醫藥科技(上海)有限公司 | Cdk9抑制劑的多晶型物及其製法和用途 |
| WO2022247796A1 (zh) * | 2021-05-24 | 2022-12-01 | 石药集团中奇制药技术（石家庄）有限公司 | 周期蛋白依赖性激酶9抑制剂的用途 |
| WO2022247785A1 (zh) * | 2021-05-24 | 2022-12-01 | 石药集团中奇制药技术（石家庄）有限公司 | 一种周期蛋白依赖性激酶9抑制剂的用途 |
| CN117813289A (zh) * | 2021-07-14 | 2024-04-02 | 上海海雁医药科技有限公司 | 吡唑衍生物及其中间体和制备方法 |
| TW202333679A (zh) * | 2021-12-23 | 2023-09-01 | 比利時魯汶大學 | 用於抑制ｙａｐ／ｔａｚ－ｔｅａｄ之四氫吡唑并嘧啶及相關類似物 |
| WO2024039210A1 (ko) | 2022-08-17 | 2024-02-22 | 한국화학연구원 | Cdk2 및/또는 cdk9의 억제 또는 분해용 화합물 및 이들의 의약 용도 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008133192A1 (ja) | 2007-04-19 | 2008-11-06 | Takeda Pharmaceutical Company Limited | 縮合イミダゾール化合物およびその用途 |
| JP5566879B2 (ja) | 2007-04-24 | 2014-08-06 | インゲニウム ファーマシューティカルズ ジーエムビーエイチ | プロテインキナーゼの阻害剤 |
| US8436007B2 (en) | 2007-04-24 | 2013-05-07 | Ingenium Pharmaceuticals Gmbh | Inhibitors of protein kinases |
| EP2137166B1 (en) | 2007-04-24 | 2012-05-30 | Ingenium Pharmaceuticals GmbH | 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases |
| WO2008129071A1 (en) | 2007-04-24 | 2008-10-30 | Ingenium Pharmaceuticals Gmbh | Inhibitors of protein kinases |
| WO2008132138A1 (en) | 2007-04-25 | 2008-11-06 | Ingenium Pharmaceuticals Gmbh | Derivatives of 4,6-disubstituted aminopyrimidines |
| BRPI0818543A2 (pt) | 2007-10-12 | 2018-10-23 | Ingenium Pharmaceuticals Gmbh | inibidores de proteína cinase |
| EP2473502A1 (en) | 2009-09-04 | 2012-07-11 | Novartis AG | Heteroaryl compounds as kinase inhibitors |
| US20110113038A1 (en) | 2009-11-12 | 2011-05-12 | International Business Machines Corporation | Search term security |
| GB201002911D0 (en) | 2010-02-19 | 2010-04-07 | Medical Res Council | Compound |
| NZ627520A (en) | 2010-03-10 | 2015-10-30 | Astrazeneca Ab | 4-phenyl pyridine analogues as protein kinase inhibitors |
| AR081810A1 (es) | 2010-04-07 | 2012-10-24 | Bayer Cropscience Ag | Piridinilpirazoles biciclicos |
| WO2012066065A1 (en) | 2010-11-17 | 2012-05-24 | Novartis Ag | Phenyl-heteroaryl amine compounds and their uses |
| EP2668162A1 (en) * | 2011-01-28 | 2013-12-04 | Novartis AG | Substituted bi-heteroaryl compounds as cdk9 inhibitors and their uses |
| WO2012101064A1 (en) * | 2011-01-28 | 2012-08-02 | Novartis Ag | N-acyl pyrimidine biaryl compounds as protein kinase inhibitors |
| WO2012101063A1 (en) | 2011-01-28 | 2012-08-02 | Novartis Ag | N-acyl pyridine biaryl compounds and their uses |
| MX351460B (es) | 2011-10-06 | 2017-10-16 | Bayer Ip Gmbh | Heterociclilpiri(mi)dinilpirazol. |
| AU2014244263A1 (en) | 2013-03-13 | 2015-08-13 | Abbvie Inc. | CDK9 kinase inhibitors |
| CA2901334A1 (en) | 2013-03-13 | 2014-10-02 | Abbvie Inc. | Pyridine cdk9 kinase inhibitors |
| MX2015012153A (es) | 2013-03-14 | 2015-12-01 | Abbvie Inc | Inhibidores de la quinasa pirrolopirimidina cdk9. |
| TW201444836A (zh) | 2013-03-14 | 2014-12-01 | Abbvie Inc | 吡咯并［２，３－ｂ］吡啶ｃｄｋ９激酶抑制劑 |
-
2016
- 2016-06-27 ES ES16733459T patent/ES2728356T3/es active Active
- 2016-06-27 HR HRP20211970TT patent/HRP20211970T1/hr unknown
- 2016-06-27 PE PE2017002874A patent/PE20180530A1/es unknown
- 2016-06-27 PT PT191657261T patent/PT3539961T/pt unknown
- 2016-06-27 HU HUE16733459A patent/HUE043440T2/hu unknown
- 2016-06-27 SI SI201630247T patent/SI3313838T1/sl unknown
- 2016-06-27 BR BR122019013677-7A patent/BR122019013677B1/pt active IP Right Grant
- 2016-06-27 DK DK16733459.8T patent/DK3313838T3/da active
- 2016-06-27 KR KR1020187002262A patent/KR102663113B1/ko active IP Right Grant
- 2016-06-27 AU AU2016286200A patent/AU2016286200B2/en active Active
- 2016-06-27 TR TR2019/09286T patent/TR201909286T4/tr unknown
- 2016-06-27 EP EP16733459.8A patent/EP3313838B1/en active Active
- 2016-06-27 PL PL16733459T patent/PL3313838T3/pl unknown
- 2016-06-27 SI SI201631427T patent/SI3539961T1/sl unknown
- 2016-06-27 WO PCT/EP2016/064899 patent/WO2017001354A1/en active Application Filing
- 2016-06-27 ES ES19165726T patent/ES2902148T3/es active Active
- 2016-06-27 ME MEP-2019-138A patent/ME03404B/me unknown
- 2016-06-27 MX MX2017016244A patent/MX371034B/es active IP Right Grant
- 2016-06-27 CR CR20210297A patent/CR20210297A/es unknown
- 2016-06-27 EP EP19165726.1A patent/EP3539961B1/en active Active
- 2016-06-27 HU HUE19165726A patent/HUE057343T2/hu unknown
- 2016-06-27 TN TNP/2017/000486A patent/TN2017000486A1/en unknown
- 2016-06-27 US US15/193,826 patent/US9845331B2/en active Active
- 2016-06-27 CA CA2989499A patent/CA2989499C/en active Active
- 2016-06-27 PT PT16733459T patent/PT3313838T/pt unknown
- 2016-06-27 CN CN201680029447.9A patent/CN107873028B/zh active Active
- 2016-06-27 LT LTEP16733459.8T patent/LT3313838T/lt unknown
- 2016-06-27 LT LTEP19165726.1T patent/LT3539961T/lt unknown
- 2016-06-27 RS RS20190564A patent/RS58712B1/sr unknown
- 2016-06-27 PL PL19165726T patent/PL3539961T3/pl unknown
- 2016-06-27 JP JP2017567737A patent/JP6997627B2/ja active Active
- 2016-06-27 DK DK19165726.1T patent/DK3539961T3/da active
- 2016-06-27 CR CR20170596A patent/CR20170596A/es unknown
- 2016-06-27 EA EA201890094A patent/EA035383B1/ru not_active IP Right Cessation
- 2016-06-27 RS RS20220005A patent/RS62781B1/sr unknown
- 2016-06-28 AR ARP160101956A patent/AR105179A1/es unknown
- 2016-06-28 TW TW105120362A patent/TWI723028B/zh active
-
2017
- 2017-12-06 US US15/833,277 patent/US10717746B2/en active Active
- 2017-12-12 DO DO2017000295A patent/DOP2017000295A/es unknown
- 2017-12-15 PH PH12017502334A patent/PH12017502334A1/en unknown
- 2017-12-18 IL IL256393A patent/IL256393B/en unknown
- 2017-12-20 SV SV2017005598A patent/SV2017005598A/es unknown
- 2017-12-21 CL CL2017003306A patent/CL2017003306A1/es unknown
- 2017-12-22 NI NI201700174A patent/NI201700174A/es unknown
- 2017-12-28 CO CONC2017/0013713A patent/CO2017013713A2/es unknown
-
2018
- 2018-01-26 ZA ZA2018/00563A patent/ZA201800563B/en unknown
- 2018-09-25 DO DO2018000207A patent/DOP2018000207A/es unknown
-
2019
- 2019-04-19 HR HRP20190748TT patent/HRP20190748T1/hr unknown
- 2019-06-19 CY CY20191100636T patent/CY1122111T1/el unknown
-
2020
- 2020-07-17 US US16/931,786 patent/US11352369B2/en active Active
-
2021
- 2021-12-22 CY CY20211101125T patent/CY1125066T1/el unknown
-
2022
- 2022-04-27 US US17/660,935 patent/US20220340592A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125066T1 (el) | Πολυκυκλικα αμιδικα παραγωγα ως αναστολεις cdk9 | |
| CY1124489T1 (el) | Αναστολεις της hpk1 και μεθοδοι χρησης αυτων | |
| CY1125042T1 (el) | Νεα ετεροκυκλικα παραγωγα χρησιμα ως αναστολεις shp2 | |
| CY1124187T1 (el) | Ετεροκυκλικα αμιδια ως αναστολεις κινασης | |
| AR123996A2 (es) | Compuestos tricíclicos novedosos como agentes antineoplásicos | |
| CR20180579A (es) | Compuestos de 1-tetrahidropiranilcarbonil-2,3-dihidro-1h-indol para el tratamiento de cáncer | |
| CY1123866T1 (el) | Οπτοηλεκτρονικη διαταξη | |
| CY1124097T1 (el) | Κρυσταλλικο πολυμορφο της ελευθερης βασης της 2-υδροξυ-6-((2-(1-ισοπροπυλο-1η-πυραζολ-5-υλο)πυριδιν-3-υλο)μεθοξυ)βενζαλδεϋδης | |
| CY1121195T1 (el) | Παραγωγα τετραϋδροναφθαλενιου που αναστελλουνπρωτεϊνη mcl-1 | |
| CY1122478T1 (el) | Συνθεσεις που περιεχουν anti-cd38 αντισωματα και λεναλιδομιδη | |
| CY1124798T1 (el) | Υποκατεστημενα παραγωγα καρβονουκλεοζιδιων χρησιμα ως παραγοντες κατα των καρκινων | |
| CY1117374T1 (el) | Παραγωγα ιμιδαζοπυριδινης, διαδικασια για την παρασκευη αυτων και θεραπευτικη χρηση αυτων | |
| CY1121804T1 (el) | Καινοτομες ενωσεις πυριμιδινης και πυριδινης και η χρηση τους | |
| CY1117197T1 (el) | Ενωσεις τριαζολοπυριδινης ως αναστολεις της κινασης ριμ | |
| PE20160995A1 (es) | Inhibidores de syk | |
| AR104326A1 (es) | Compuestos nucleósidos 5-sustituidos | |
| CY1125047T1 (el) | Διεργασιες για την παρασκευη ενωσεων τυπου οξαθειαζινης | |
| MX365590B (es) | Metodos para preparar 6-(aril o heteroaril)-1,3,5-triazin-2,4-diol es y 6-(aril o heteroaril)-1,3,5-triazin-2,4-diaminas. | |
| NZ748260A (en) | Substituted pyrimidine bmi-1 inhibitors | |
| CY1113812T1 (el) | Ετεροκυκλικη ενωση και φαρμακευτικη συνθεση αυτης | |
| CY1125082T1 (el) | Υποκατεστημενα τριαζολια και μεθοδοι που σχετιζονται με αυτα | |
| CY1121885T1 (el) | Αντι-ογκικες ενωσεις | |
| IN2014MN02107A (el) | ||
| CY1123927T1 (el) | Παραγωγο 5-μεθυλ-6-φαινυλ-4,5-διυδρο-2η-πυριδαζιν-3-ονης για τη θεραπεια ογκων του εγκεφαλου | |
| CY1124308T1 (el) | Παραγωγα πυραζολυλαμινοβενζιμιδαζολης ως αναστολεις της jak |